Current Environment:


The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 weeks. All participants will have the opportunity to receive intravenous (IV) delandistrogene moxeparvovec in either Part 1 or Part 2.


Duchenne Muscular Dystrophy

Recruitment Status


Eligibility Criteria

Inclusion Criteria:

Definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.
Cohort 1 only: Non-ambulatory per protocol specified criteria.
Cohort 2 only: Ambulatory per protocol specified criteria and ≥8 to <18 years of age at the time of Screening.
Ability to cooperate with motor assessment testing.
Stable daily dose of oral corticosteroids for at least 12 weeks prior to Screening, and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight).
Recombinant Adeno-Associated Virus Serotype rh74 (rAAVrh74) antibody titers are not elevated as per protocol-specified requirements.
A pathogenic frameshift mutation or premature stop codon contained between exons 18 and 79 (inclusive).

Exclusion Criteria:

Exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression within protocol specified time limits.
Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
Presence of any other clinically significant illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer.

Other inclusion or exclusion criteria could apply.


Intervention Type

Intervention Name


delandistrogene moxeparvovec




Phase 3



Min Age


Max Age


Download Date

May 10, 2024

Principal Investigator

This field has been modified from to show a contact specific to Boston Children's.

Primary Contact Information

This field has been modified from to show a contact specific to Boston Children's.

For more information on this trial, visit


For more information and to contact the study team:

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) NCT05881408